Tailored cancer cocktail fails to launch: neuroblastoma trial halted
NCT ID NCT02780128
First seen Mar 11, 2026 · Last updated May 06, 2026 · Updated 12 times
Summary
This study aimed to give children with relapsed or hard-to-treat neuroblastoma a personalized treatment plan. Doctors would analyze the tumor's genes and pick a combination of targeted drugs to attack the specific mutations found. The trial was stopped early, so results are limited, but the goal was to see if this tailored approach could shrink tumors and be safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
Conditions
Explore the condition pages connected to this study.